We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Mesoblast Receives FDA Clearance for Phase 2 Trial of MPCs in Active RA Patients
News

Mesoblast Receives FDA Clearance for Phase 2 Trial of MPCs in Active RA Patients

Mesoblast Receives FDA Clearance for Phase 2 Trial of MPCs in Active RA Patients
News

Mesoblast Receives FDA Clearance for Phase 2 Trial of MPCs in Active RA Patients

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Mesoblast Receives FDA Clearance for Phase 2 Trial of MPCs in Active RA Patients"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Mesoblast Limited has announced that it has received clearance from the United States Food and Drug Administration (FDA) to commence a Phase 2 clinical trial evaluating a single intravenous infusion of allogeneic, or “off-the-shelf”, Mesenchymal Precursor Cells (MPCs) for the treatment of active rheumatoid arthritis.

The randomized, double-blind placebo-controlled trial is expected to commence during the second quarter 2013, and will recruit across multiple sites in the United States and Australia.

The trial will compare the effects of a single intravenous infusion of allogeneic MPCs dosed at 1 or 2 million cells/kg compared with placebo in 48 patients who have had an incomplete or inadequate response to a biologic inhibitor of the TNF-alpha pathway for active rheumatoid arthritis.

Safety and effectiveness of the MPC therapy will be assessed at multiple time points with the primary endpoints defined as 3 months.

RA is an autoimmune disease caused by aberrant activation of multiple immune pathways involving both monocytes and T cells, ultimately resulting in joint destruction.

Existing biologic treatments target only single immune pathways, resulting in incomplete responses, need for chronic administration, and potentially unacceptable infectious adverse events.

In contrast, Mesoblast's MPCs have been shown in preclinical studies to have a broad immunomodulatory mechanism of action (MOA), simultaneously inhibiting T cells and monocytes involved in inflammation and autoimmunity.

The broader effects of Mesoblast's MPCs on multiple immune pathways suggest that they may be particularly useful agents for reducing the inflammation and permanent joint damage associated with progression of RA.

In a randomized, placebo-controlled study in 30 sheep with collagen-induced arthritis, a model that manifests joint damage characteristic of human RA, treatment with Mesoblast’s MPCs resulted in reduced TNF-alpha, IL-6, and IL-17 in the diseased joint.

In comparison with saline treated controls, synovial tissue from arthritic sheep 30 days after receiving a single intravenous injection of 2 million MPCs/kg showed 88% reduction in IL-6 levels (p=0.029), 83% reduction in TNF-alpha levels (p=0.049), 53% reduction in IL-17 levels (p=0.005), and 43% reduction in infiltrating monocytes/macrophages (p=0.018). MPC-treated animals had a 31% reduction in histopathology severity scores compared with controls (p <0.025).

These findings show that MPCs can concomitantly inhibit both Th17 T cells and pro-inflammatory monocytes, and improve synovial tissue pathology.

This provides a rationale for their potential use as both a first-line biologic treatment in those not responding to conventional anti-rheumatic agents and in patients with incomplete responses to biologic inhibitors of the TNF-alpha pathway alone.

Mesoblast Chief Executive Professor Silviu Itescu said: “We believe that the broad immunomodulatory effects of our MPCs could provide a tangible benefit to patients with debilitating autoimmune diseases, including RA. This is the first in a series of programs designed to establish the credentials of our intravenous product formulation for a broad-based spectrum of inflammatory and immunologic conditions.”

Advertisement